Press Releases
iCAD Releases Enhanced ProFound Detection Workstation Features to Streamline Mammogram Interpretation for Radiologists
Newly released capabilities — limiting the number of marks on a 3D view, color-coding lesion marks, and color-coding the ProFound Scorecard — enhance radiologists’ interpretability and efficiency NASHUA, N.H. – March 19, 2024 – iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers…
iCAD Announces Fiscal Fourth Quarter and Full-Year 2023
Annual Recurring Revenue of $8.7 million, an increase of 15% year-over-year Full-Year Operating Cash Flow ($5) million vs. ($12.8) million prior year Year ending cash balance of $21.7M NASHUA, N.H. – March 12, 2024 – iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical…
iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings
NASHUA, N.H. – Feb. 28, 2024 – iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, will highlight scientific presentations, including an award-winning poster at the European Congress of Radiology (ECR) annual…
iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
NASHUA, NH., February 27, 2024 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the Company will release financial results for the fourth quarter and full year…
iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, Dr.h.cm
Dr. Hricak offers extensive experience in radiology, real world application of AI enabled imaging solutions, research, and global healthcare perspectives. NASHUA, NH., February 27, 2024 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD) a global leader in providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect…
iCAD to Participate in the BTIG at Snowbird: 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
NASHUA, NH., February 6, 2024 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the Company will participate in the BTIG at Snowbird: 11th Annual MedTech, Digital…
iCAD Expands Board of Directors with Appointment of Michael J. Doyle, FACHE as New Board Member
NASHUA, NH., January 30, 2024 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the appointment of Michael J. Doyle to its Board of Directors, effective immediately….
iCAD Expands Executive Sales Leadership Team as Business Grows
Bill Keyes shifts and expands his role to Senior Vice President, Global Sales Operations and Peter Graham joins iCAD as Senior Vice President, North American Sales to accelerate growth while organization adds new products and partnerships. NASHUA, N.H., December 18, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology…
iCAD’s AI-powered solutions to Help Accelerate Breast Cancer Detection in New Collaboration with GE Healthcare
NASHUA, N.H., Nov. 28, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection solutions, today announced that key artificial intelligence (AI) powered solutions from iCAD’s ProFound Breast Health Suite are the first applications to be offered in GE HealthCare’s new MyBreastAI Suite* offering. As breast…
iCAD’s ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease
NASHUA, N.H. – Nov. 27, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection solutions, will present new studies validating its artificial intelligence (AI) powered ProFound Breast Health Suite for uncovering hidden heart or vascular disease and predicting a woman’s risk for developing breast cancer…